Kistler Tiffany Companies LLC reduced its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,424 shares of the medical research company’s stock after selling 137 shares during the quarter. Amgen comprises approximately 1.0% of Kistler Tiffany Companies LLC’s holdings, making the stock its 19th largest position. Kistler Tiffany Companies LLC’s holdings in Amgen were worth $2,995,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of AMGN. New England Research & Management Inc. bought a new position in shares of Amgen in the fourth quarter worth $230,000. Monument Capital Management grew its stake in shares of Amgen by 0.8% in the fourth quarter. Monument Capital Management now owns 8,292 shares of the medical research company’s stock worth $1,999,000 after purchasing an additional 66 shares in the last quarter. Belmont Capital LLC bought a new position in shares of Amgen in the fourth quarter worth $36,000. Atlantic Union Bankshares Corp grew its stake in shares of Amgen by 6.2% in the fourth quarter. Atlantic Union Bankshares Corp now owns 3,730 shares of the medical research company’s stock worth $899,000 after purchasing an additional 219 shares in the last quarter. Finally, Webster Bank N. A. grew its stake in shares of Amgen by 1.3% in the fourth quarter. Webster Bank N. A. now owns 3,870 shares of the medical research company’s stock worth $933,000 after purchasing an additional 48 shares in the last quarter. Hedge funds and other institutional investors own 76.58% of the company’s stock.

In other news, Director R Sanders Williams sold 425 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $215.45, for a total transaction of $91,566.25. Following the completion of the sale, the director now directly owns 5,413 shares of the company’s stock, valued at $1,166,230.85. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO David W. Meline sold 8,737 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $234.36, for a total value of $2,047,603.32. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 18,162 shares of company stock valued at $4,214,030. 0.25% of the stock is currently owned by company insiders.

Several research analysts have recently issued reports on the company. Goldman Sachs Group set a $243.00 price target on Amgen and gave the stock a “buy” rating in a research note on Monday, September 30th. Sanford C. Bernstein initiated coverage on Amgen in a report on Monday, October 14th. They issued an “outperform” rating for the company. Royal Bank of Canada restated a “hold” rating on shares of Amgen in a report on Monday, September 30th. SunTrust Banks initiated coverage on Amgen in a report on Tuesday, November 12th. They issued a “buy” rating and a $256.00 price objective for the company. Finally, Bank of America initiated coverage on Amgen in a report on Wednesday, October 16th. They issued a “neutral” rating and a $215.00 price objective for the company. Eleven equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $235.39.

Shares of Amgen stock traded up $3.08 during trading on Tuesday, hitting $240.00. The stock had a trading volume of 2,169,776 shares, compared to its average volume of 1,877,842. Amgen, Inc. has a fifty-two week low of $166.30 and a fifty-two week high of $244.99. The firm has a market cap of $141.57 billion, a P/E ratio of 16.67, a PEG ratio of 2.07 and a beta of 1.11. The company has a debt-to-equity ratio of 2.54, a current ratio of 2.89 and a quick ratio of 2.59. The business has a fifty day moving average of $238.06 and a two-hundred day moving average of $208.24.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, October 29th. The medical research company reported $3.66 EPS for the quarter, beating the consensus estimate of $3.53 by $0.13. Amgen had a return on equity of 80.26% and a net margin of 34.48%. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.63 billion. During the same period in the prior year, the business posted $3.69 earnings per share. Amgen’s revenue was down 2.8% compared to the same quarter last year. As a group, research analysts forecast that Amgen, Inc. will post 14.58 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 14th will be issued a dividend of $1.60 per share. This represents a $6.40 annualized dividend and a dividend yield of 2.67%. This is an increase from Amgen’s previous quarterly dividend of $1.45. The ex-dividend date is Thursday, February 13th. Amgen’s dividend payout ratio is currently 40.28%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Article: What is the Euro STOXX 50 Index?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.